Skip to content
naulon

No retraction, correction or concern found when last checked on Oct 17, 2026.

Betaine in Inflammation: Mechanistic Aspects and Applications

Guangfu Zhao, Fang He, Chenlu Wu and 6 more

Frontiers in Immunology · 2018 · Review

doi:10.3389/fimmu.2018.01070

Abstract

Betaine is known as trimethylglycine and is widely distributed in animals, plants, and microorganisms. Betaine is known to function physiologically as an important osmoprotectant and methyl group donor. Accumulating evidence has shown that betaine has anti-inflammatory functions in numerous diseases. Mechanistically, betaine ameliorates sulfur amino acid metabolism against oxidative stress, inhibits nuclear factor-κB activity and NLRP3 inflammasome activation, regulates energy metabolism, and mitigates endoplasmic reticulum stress and apoptosis. Consequently, betaine has beneficial actions in several human diseases, such as obesity, diabetes, cancer, and Alzheimer's disease.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 17, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

Betaine is a stable and nontoxic natural substance. Because it looks like a glycine with three extra methyl groups, betaine is also called trimethylglycine. In addition, betaine has a zwitterionic quaternary ammonium form [(CH3)3N+ CH2COO−] (Figure 1). In the nineteenth century, betaine was first identified in the plant Beta vulgaris. It was then found at high concentrations in several other organisms, including wheat bran, wheat germ, spinach, beets, microorganisms, and aquatic invertebrates. Dietary betaine intake plays a decisive role in the betaine content of the body. Betaine is safe at a daily intake of 9–15 g for human and distributes primarily to the kidneys, liver, and brain. The accurate amount of betaine intake generally relies on its various sources and cooking methods. Besides dietary intake, betaine can be synthesized from choline in the body. Studies report that high concentrations of betaine in human and animal neonates indicate the effectiveness of this synthetic mechanism.

Regarding its biological significance, on the one hand, betaine is a vital methyl group donor in transmethylation, a process catalyzed by betaine-homocysteine methyltransferase (BHMT). This reaction catalyzes homocysteine to form methionine and occurs primarily in the liver and kidneys. On the other hand, betaine is an essential osmoprotectant, primarily in the kidneys, liver, and brain, and large amounts of betaine can accumulate in cells without disrupting cell function; importantly, this role of betaine protects cells, proteins, and enzymes under osmotic stress.

Recently, several studies have focused on various natural compounds proven to be effective against many diseases. For example, Geng and colleagues found that mulberrofuran G has anti-hepatitis B virus activity. Interestingly, in Southeast Asia, water extracts of Lycium chinensis, which contains a high concentration of betaine, were used as a traditional oriental medicine to treat liver disorders. These findings indicate that the function of betaine, a natural compound, has become a hot topic because of its anti-inflammatory effects on diseases, such as nonalcoholic and alcoholic fatty liver disease (NAFLD and AFLD) and diabetes. This paper summarizes the role of betaine in physiological functions, anti-inflammatory mechanisms, and human diseases.

Physiological Functions of Betaine

As many studies show, cells from bacteria to vertebrates absorb betaine as an osmoprotectant; animals can rapidly absorb betaine through the duodenum of the small intestine. Specifically, betaine can be freely filtered in the kidney and reabsorbed into the circulation, so it is primarily excreted in sweat instead of urine. Betaine accumulation depends on transporters, and it primarily distributes to the kidneys, liver, and brain. Although betaine is utilized in most tissues (such as the kidneys and brain) as an osmoprotectant, its primary role is to act as a methyl group donor in liver metabolism.

Betaine as an Osmoprotectant

In contrast to inorganic salts, osmoprotectants are highly soluble small organic compounds that accumulate in large amounts in cells without disrupting cell function; these compounds protect against osmotic stress. Hyperosmosis can cause water efflux and a concomitant reduction in cell volume; these effects are detrimental to cell survival. Thus, to balance hyperosmosis and protect cells from shrinkage and death, the accumulation of different types of osmoprotectants, such as betaine, sorbitol, and taurine, is essential. In contrast to other osmolytes and inorganic salts, such as urea and Na+, betaine reduces the ability of water molecules to solvate proteins, thus stabilizing the native protein structures. In addition, betaine can also increase the cytoplasmic volume and free water content of cells to prevent shrinkage in hyperosmotic conditions and to inhibit various hyperosmotic-induced apoptosis-related proteins. Due to these advantages, additional betaine can be used to counter the pressure when tissues are hypertonic. For example, in the kidneys, hypertonicity increases the levels of the betaine-γ-aminobutyric acid (GABA) transport system (GAT4/BGT1) in the basolateral plasma membrane to obtain more betaine; however, under normal physiological conditions, BGT1 levels are low, and this transporter is present primarily in the cytoplasm in Madin–Darby canine kidney (MDCK) cells.

Betaine as a Methyl Group Donor

Betaine is not only a metabolite of choline but also a methyl group donor that participates in methylation. Methylation, such as that of DNA and protein, is an essential biochemical process in animals. A previous study has shown that the availability of methyl group donors influences methylation levels. It has been acknowledged that betaine, methionine, and choline are the most important methyl group donors present in diets. Nevertheless, the major role of methionine is a substrate for protein synthesis, and choline contributes primarily to forming the cell membrane and neurotransmitters. The transmethylation reaction of betaine, which is part of a one-carbon metabolism via the methionine cycle, occurs principally in the mitochondria of liver and kidney cells. In this reaction, BHMT catalyzes the addition of a methyl group from betaine to homocysteine to form methionine, which is subsequently converted to dimethylglycine (DMG). DMG has two available methyl groups and is possibly degraded to sarcosine and ultimately to glycine. Similarly, methionine synthase (MS), a vitamin B12-dependent enzyme, can also catalyze the formation of methionine from homocysteine with a donor methyl group from N5-methyltetrahydrofolate. These reactions are important in animals because they conserve methionine, detoxify homocysteine, which is a cause of cardiovascular disease, and produce S-adenosylmethionine (SAM). SAM is generated from methionine via methionine adenosyltransferase (MAT), and SAM is a principal methylating agent. After demethylation, SAM is transformed into S-adenosylhomocysteine (SAH). The ratio of SAM:SAH affects various SAM-dependent methyltransferases, including protein-L-isoaspartate methyltransferase (PIMT), phosphatidylethanolamine methyltransferase (PEMT), protein arginine methyltransferase (PRMT), and isoprenylcysteine carboxyl methyltransferase (ICMT). These enzymes are associated with the protein repair progress, lipid metabolism, protein–protein interactions, and GTPase activity. One molecule of SAH is subsequently hydrolyzed by SAH hydrolase to form one homocysteine molecule and one adenosine molecule. Notably, this reaction is reversible, and the direction of the reaction depends on whether these products are removed. All of these reactions constitute the methionine cycle. Furthermore, with the help of cystathionine β-synthase, a vitamin B-6-dependent enzyme, homocysteine can be transformed into cystathionine via the transsulfuration pathway. In this pathway, homocysteine catabolism leads to an increase in the production of glutathione (GSH), taurine, and other metabolites. Dietary betaine supplementation has been demonstrated to have an impact on various sulfur amino acids (SAAs). For example, such supplementation effectively increases the available methionine and SAM. Therefore, betaine acts as a methyl donor and plays an influential role in SAA metabolism; the details of this metabolic pathway are shown in Figure 1B.

Anti-Inflammatory Effects of Betaine on Diseases

Inflammation, an immune reaction, is an essential and primary process of host defense and wound healing. However, excessive or prolonged inflammation may become the pathogenesis of various diseases. Due to this, using natural compounds to treat diseases could be a good strategy by controlling the intensity of the inflammatory reaction. For instance, many studies show that GABA is anti-inflammatory. Consequently, using betaine in response to inflammation has sparked heated debate in recent years. Next, this review will discuss the primary mechanisms through which betaine exerts its anti-inflammatory effects on diseases.

Betaine Ameliorates SAA Metabolism Against Oxidative Stress

Reactive oxygen species (ROS) are by-products of biological energy-generating reactions; in particular, they are produced in the mitochondria where oxidative metabolism primarily occurs. Under normal conditions, the body has two detoxification systems that can clear ROS and free radicals: antioxidant enzymes and antioxidant agents. Catalase, superoxide dismutase (SOD), melatonin, and GSH are examples of these detoxification agents. However, excess ROS levels are a threat to cells because they alter the stability of nucleic acids, proteins, and the lipid membrane; furthermore, high ROS levels likely cause pathological processes, including inflammation.

Sulfur amino acids such as homocysteine, methionine, SAM, SAH, and cysteine are involved in various essential metabolic pathways, including GSH synthesis and protein synthesis, and transmethylation reactions. Although homocysteine contributes to GSH synthesis, various studies have demonstrated that hyperhomocysteinemia ultimately induces oxidative stress and apoptosis. Betaine treatment can directly influence homocysteine concentrations via stimulating homocysteine to form methionine to regulate SAA concentrations. For example, ethanol-induced ROS and free radicals can suppress methionine synthase (MS) activity to inhibit remethylation and induce hyperhomocysteinemia. To compensate for this decrease in MS activity, betaine was used as an alternate methyl donor that improved BHMT activity to generate methionine and SAM and remove homocysteine in the livers of ethanol-fed Wistar rats. However, it is worth noting that C57B6 mice showed a decrease or no change in BHMT expression, rather than a compensational increase. As betaine converts homocysteine to methionine, methionine concentrations are closely related with betaine. Methionine plays an important role in antioxidation. For example, methionine can reduce oxidative stress via chelation, and it can be used by hepatocytes for GSH synthesis. In addition, this reaction is essential for generating SAM and removing homocysteine. Studies have demonstrated that SAM is a direct antioxidant in the body and that it can modulate GSH metabolism. Moreover, based on the reversibility of the reaction that converts SAH to homocysteine and adenosine, homocysteine concentrations would further decrease. SAH is a powerful inhibitor of SAM-dependent methyltransferases; which methylate various compounds, such as nucleic acids and proteins. Kwon and colleagues found that betaine could significantly increase the SAM:SAH ratio and MAT activity. Kharbanda and colleagues found that betaine could prevent nitric oxide synthase 2(NOS2) expression; this process is initiated by inflammation, and the SAM:SAH ratio is increased to maintain NOS2 promoter methylation. In addition, homocysteine can also be converted to cysteine via the irreversible transsulfuration pathway, and cysteine then forms either taurine via cysteine dioxygenase (CDO) or GSH via γ-glutamylcysteine synthetase. Researchers found that betaine treatment inhibited CDO activity and decreased taurine levels, while increased the production of GSH to neutralize oxidative stress in AFLD and NAFLD mice.

Few studies indicated antioxidant enzymes, such as SOD 2 and glutathione S-transferases (GST), were changed after betaine treatment, but most results have shown no significant changes. Thus, more researches are needed in the future to confirm whether these antioxidant enzymes really participated in the process. Considering the above studies, the primary antioxidant mechanism of betaine may occur through ameliorating SAA metabolism. These changes after betaine treatment and the oxidation-related functions of primary SAAs are shown in Table 1.

Betaine Inhibits the NF-κB Signaling Pathway

The pathway of the transcription factor nuclear factor-κB (NF-κB) controls many genes involved in inflammation; these genes include the pro-inflammatory cytokines tumor necrosis factor-alpha (TNF-α), interleukin 1 beta (IL-1β) and interleukin 23 (IL-23). Therefore, it is not surprising that many inflammatory diseases involve chronically activation of NF-κB. Consequently, the NF-κB pathway has become an essential candidate for inflammation treatment. Researchers found that betaine can suppress NF-κB activity and various downstream genes. For example, in an early study of aged kidneys, betaine treatment suppressed NF-κB activity and the expression of a variety of related genes, including TNF-α, vascular cell adhesion molecule-1 (VCAM-1), intracellular cell adhesion molecule-1 (ICAM-1), inducible nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-2). Notably, in this and another study about atherogenesis, the authors found that betaine inhibited NF-κB by suppressing two important activators, mitogen-activated protein kinases (MAPKs) and nuclear factor-inducing kinase/IκB kinase (NIK/IKK). NIK/IKK can relieve IκB inhibition and initiate the transcriptional activation of NF-κB. MAPKs consist of c-Jun NH2-terminal kinase (JNK), protein 38 (p38), and extracellular signal-regulated kinase (ERK1/2) and are involved in inflammation and the response to pro-inflammatory cytokine expression. Mechanistically, betaine exerts its effects by maintaining thiol levels, particularly GSH, to inhibit ROS production and NF-κB activity. Furthermore, betaine also inhibits some upstream signaling molecules that induce the activation of NF-κB. Classically, Toll-like receptors (TLRs) participate in an important upstream signaling event, which eventually culminates in activating NF-κB. In an in vitro study, betaine treatment prevented lipopolysaccharide (LPS, specific activator of TLR-4)-induced NF-κB activation in RAW 264.7 murine macrophage cells. Another study showed that betaine treatment improved hypothalamic neural injury via inhibiting the TLR-4/NF-κB signaling pathway to restore fructose-induced astrogliosis and inflammation. This study suggests that betaine can inhibit histone deacetylases 3 expression, which can activate NF-κB via binding to IκBα. Another study showed that betaine treatment can reduce the mRNA and protein expression levels of high-mobility group box 1, a positive regulator of TLR-4 activation to restrict inflammation. In addition, betaine can also reduce endogenous damage-associated molecular pattern (DAMP) generation to inhibit the NF-κB pathway. In conclusion, betaine has anti-inflammatory effects through its inhibition of NF-κB signaling pathway.

Betaine Inhibits NLRP3 Inflammasome Activation

The leucine-rich family, pyrin-containing 3 (NLRP3) inflammasome is a large cytosolic protein complex that contains the nucleotide-binding domain, leucine-rich repeat-containing (NLR) family member NLRP3, the important adapter molecule ASC, and mature caspase-1. When TLRs recognize DAMPs or pathogen-associated molecular patterns, NF-κB can be activated to promotes mRNA expression of interleukin precursors, including pro-IL-18 and pro-IL-1β, as well as NLRP3. The completely assembled NLRP3 inflammasome activates caspase-1 to mediate the production of mature IL-1β and IL-18, which are involved in initiating inflammation. It is important to ameliorate inflammatory reactions via inhibiting NLRP3 inflammasome activity.

Earlier studies have shown that betaine can directly increase heme oxygenase-1 expression levels in hepatocytes; this effect may suppress the NLRP3 inflammasome to protect against LPS-induced and d-galactosamine-induced inflammation in the liver. Recent studies have demonstrated that betaine treatment can significantly inhibit NLRP3 inflammasome-related proteins, such as NLRP3 and mature caspase-1, and the levels of pro-inflammatory cytokines, including IL-1β, in a dose-independent manner in fructose-induced NAFLD models. The same phenomenon was found in betaine-treated db/db mice; this finding shows that the mechanism is associated with a forkhead box O1 (FOXO-1) inhibition of thioredoxin-interacting protein (TXNIP), which can promote the production of ROS to trigger NLRP3 inflammasome assembly. The FOXO family contains six members, including FOXO-1 and FOXO-6, that are found in mammals. The main role of FOXO factors is the regulation of cell growth, cell death, proliferation, differentiation, and oxidative stress response. Activated FOXO-1 promotes TXNIP activity, which is the endogenous inhibitor of ROS-scavenging protein thioredoxin, resulting in producing more ROS. In addition, activated PKB/Akt can phosphorylate the active form of FOXO-1 to trigger its exit from the nucleus into the cytoplasm; this change makes FOXO-1 inactivation. In this study, betaine treatment increased the levels of PKB/Akt-mediated FOXO-1 phosphorylation. However, Kathirvel and colleagues noted that betaine did not directly activate PKB/Akt, and its mechanism may be the result of enhanced insulin receptor substrate 1 (IRS-1) phosphorylation. Thus, we suggest that betaine could enhance IRS-1 activity to activate PKB/Akt; then, the activated PKB/Akt would inhibit FOXO-1 activation, which restricts TXNIP to suppress NLRP3 inflammasome components to excise its anti-inflammation effects. Moreover, a study found that betaine mediated inhibition of NLRP3 inflammasome activation played a more important role than that of NF-κB in response to renal inflammation. Overall, the anti-inflammatory effects of betaine are closely associated with its inhibition of NLRP3 inflammasome activation.

Betaine Regulates Energy Metabolism to Relieve Chronic Inflammation

Energy metabolism disorders can lead to various chronic diseases, including obesity and diabetes, which generally have a systemic low-grade inflammation. Thus, restoring normal metabolism is an essential step that contributes to mitigating inflammation. As various reports have reported, betaine has effects on both lipid and glucose metabolism. Regarding lipid metabolism, excessive fat accumulation resulting from the imbalance of lipid transportation, synthesis, and oxidation is considered to be the culprit of many diseases. Many studies have demonstrated that various factors, such as high-fat diets, antibiotics exposure and ethanol consumption, could lead to such situations.

Betaine treatment can restore the imbalance between synthesis and oxidation to help attenuate fat accumulation. Song and colleagues found that an increased hepatic AMP-activated protein kinase (AMPK) activity may be involved mechanistically. AMPK serves as both a principal cellular energy sensor and a vital metabolic homeostasis regulator; in fact, AMPK controls many genes, such as sterol regulatory element-binding protein-1c (SREBP-1c), acetyl CoA carboxylase (ACC), and fatty acid synthase (FAS). Activated AMPK can inhibit fatty acid synthesis and promote fatty acid oxidation via regulating the expression of these genes. Betaine can increase AMPK phosphorylation and then inhibit ACC activity as well as SREBP-1c and FAS expression. This result supports the finding of another study in which AMPK could directly phosphorylate SREBP-1c and SREBP-2 at Ser372 to inhibit their activities to reduce lipogenesis and lipid accumulation in diet-induced insulin-resistant mice. Furthermore, activated AMPK promotes glucose uptake via improving glucose transporter type 4 (GLUT-4) translocation; these findings suggest a beneficial effect on insulin resistance. Regarding the mechanism of AMPK activation, changing the AMP:ATP ratio in cells under normal conditions activates AMPK. However, hepatic AMPK activation can occur independently of the AMP:ATP ratio via adiponectin. Interestingly, in another study from Song, betaine could restore abnormal adipokine levels in NAFLD, and it upregulated adiponectin and downregulated leptin and resistin in adipose cells to attenuate the dysregulated lipid metabolism. Similar effects of betaine are supported by another in vitro study in human adipocytes. These results imply that the upregulation of adiponectin may contribute to AMPK phosphorylation. In addition, because these adipokines play roles in inflammation, this normalizing process is anti-inflammatory. In addition to activating AMPK, betaine treatment could potentially influence other lipid metabolism-related factors. Earlier studies showed that betaine can reduce triglyceride accumulation in apolipoprotein B (apoB)-deficient mice via decreasing peroxisomal proliferator-activated receptor alpha (PPARα) methylation. In another study, betaine restricted PPARγ transcriptional activity via inhibiting FOXO-1 binding to the PPARγ promoter to reduce fat accumulation. In a recent study, not only PPARα but also hepatic liver X receptor α (LXRα) were upregulated when betaine restored fatty acid oxidation inhibition. Although the mechanism of how betaine activates LXRα remains unclear, it may be associated with a SAM-related enzyme PRMT-3, which can directly increase LXRα activity. In addition, in a study of cisplatin-induced nephrotoxicity, betaine inhibited lipid peroxidation via suppressing renal thiobarbituric acid-reactive substance activation, which is mostly initiated by oxidative stress. In addition to altering fat synthesis and oxidation, betaine treatment can ameliorate lipid transport. A study found that betaine maintains liver SAM:SAH ratios to enhance phosphatidylcholine synthesis and normalize very-low-density lipoprotein (VLDL) production via promoting PEMT activity, and another study found that betaine stimulates apoB gene expression to form more VLDL.

With respect to glucose metabolism, studies have demonstrated that insulin resistance is associated with inflammation. Morgan and colleagues discovered that betaine supplementation could directly act upon the insulin pathway to improve NAFLD. A similar phenomenon has been found in another study of type 2 diabetes. In these studies, betaine significantly reduced ser473-phosphorylated PKB/Akt levels, but it increased IRS-1 phosphorylation and thr308-phosphorylated PKB/Akt levels. The PKB/Akt regulates systemic and cellular metabolism, mainly by mediating cell proliferation, differentiation, and survival, and it is required for insulin signaling. Then, thr308-phosphorylated PKB/Akt could restrict FOXO-1 and glycogen synthase kinase-3α activities. The former can decrease the expression levels of phosphoenolpyruvate carboxy kinase to reduce hepatic gluconeogenesis, whereas the latter can increase glycogen synthesis. To verify whether betaine can directly initiate PKB/Akt, the authors used a PI3K inhibitor, wortmannin, and found it hard to detect activated PKB/Akt; these results suggest that betaine may directly enhance IRS-1 phosphorylation rather than directly activate PKB/Akt. The mechanism of how betaine enhances IRS-1 phosphorylation to improve insulin resistance remains unclear. However, Iwasaki and colleagues recently reported that PRMT-1 can methylate heterogeneous nuclear ribonucleoprotein (hnRNPQ) and may be involved in insulin signaling. Mechanistically, PRMT-1 can catalyze the addition of a methyl group from SAM to hnRNPQ; this process results in internalization and lasting insulin receptor activation. Notably, SAM concentrations are associated with betaine. Therefore, these evidences speculated that betaine could improve the available SAM to generate more methylation hnRNPQ via PRMT-1 and thus PKB/Akt activation. Besides IRS-PKB/Akt signaling pathway, Chen and colleagues found that betaine treatment could reduce the protein levels of X-box-binding protein-1, an endoplasmic reticulum (ER) stress-related protein; this reduction is likely to enhance p38–MAPK and mammalian target of rapamycin activities and ultimately reduce hepatic gluconeogenesis and insulin resistance. Therefore, we conclude that betaine exerts its anti-inflammatory effects via restoring energy metabolism. These main metabolic pathways and key factors mediated by betaine treatment in chronic inflammation are shown in Table 2.

Betaine Mitigates ER Stress and Apoptosis

Endoplasmic reticulum (ER) stress is caused by the abnormal assembly of proteins, as either misfolded or unfolded proteins, in the ER lumen. Various proteins, such as C/EBP homologous protein (CHOP) and glucose-regulated protein 78 (GRP78), are involved in ER stress, and both of these proteins are ER stress markers. Massive ER stress is undesirable and leads to cell apoptosis. Apoptosis is a type of cell death, and takes part in the pathogenesis of inflammatory diseases. Although apoptosis has extrinsic and intrinsic pathways, the final process is completed by caspase family proteins, especially caspase-3.

As mentioned, betaine can directly influence the homocysteine pool, and it has been reported that hyperhomocysteine can induce misfolded proteins, ultimately leading to ER stress. According to the research by Cheng, betaine can stabilize homocysteine levels and inhibit GRP78 and CHOP levels as well as cell death. Likewise, in another study, betaine inhibited both GRP78 and CHOP and reduced JNK activation. Interestingly, the JNK pathway can directly phosphorylate multiple IRS-1 sites, including serine-307. These modifications prevent insulin-stimulating IRS-1 tyrosine phosphorylation, which leads to insulin resistance. In addition to ER stress, betaine also inhibits apoptosis. In a recent study of rheumatoid arthritis synovial fibroblasts, Gaur and colleagues found that transcription factor-3 (ATF-3), an apoptosis-related molecule, is downregulated by betaine. In addition, betaine can inhibit caspase family proteins. In an in vitro study, adding adenosine to hepatocytes increased hepatic SAH levels and caspase-3 activity, both of which would be inhibited by betaine treatment. The inhibition of caspase-3 by betaine is also found in cisplatin-induced nephrotoxicity. Furthermore, betaine significantly reduced caspase-8, caspase-9, and caspase-3/7 activity in human corneal epithelial cells and MDCK cells under hyperosmotic stress. Thus, we would like to believe that the mitigation of ER stress and apoptosis by betaine is essential to its anti-inflammatory effects.

Applications of Betaine in Human Diseases

Recently, the effects of natural and nontoxic substances on human diseases have attracted considerable attention. Researches have shown that betaine has beneficial effects in various human diseases, such as obesity, diabetes, cancer, and Alzheimer’s disease. Obesity results from excessive fat accumulation and has potentially negative effects on health. Obesity can lead to various secondary diseases, such as NAFLD. In animal studies, dietary betaine has been demonstrated to positively affect body fat. However, few studies have focused on the effect of betaine on human obesity, and some of the results are contradictory. The current studies show that plasma betaine concentrations are inversely correlated with body fat percentages in adults; subjects with higher plasma betaine concentrations tended to have better fat profiles and distributions. In a recent study, Gao and colleagues found that this positive correlation between plasma betaine concentrations and a better body composition existed in only males. Although this area deserves attention, there are few studies exploring the influence of betaine supplementation on obesity. In the studies of Schwab and Favero, betaine supplementation did not affect body composition. However, in another study from Gao and colleagues, a large general population was analyzed, and a higher betaine intake was correlated with a better body composition. Similarly, other studies show that plasma betaine concentrations are inversely associated with human NAFLD, but the results of betaine supplementation are up for debate. Thus, in order to get the reliable result, more studies need to focus on this area from now on. In addition, many animal studies have shown that betaine is closely linked with diabetes. Diabetes leads to hyperglycemia due to impaired glucose metabolism. Different from its role in obesity, plasma betaine concentration is a poor predictor for diagnosing diabetes in humans. Nevertheless, plasma betaine concentration is likely linked with secondary diseases of diabetes, such as microangiopathy. Studies have shown that abnormal urinary betaine excretion is closely associated with diabetes, but its diagnostic value is lower than that of other substances, such as choline and DMG. Currently, only one study has investigated the effect of betaine supplementation on diabetes. Therefore, to identify whether betaine supplementation is effective, more systematic studies will be needed in the future. Various human studies have found that in addition to its association with metabolic diseases, betaine intake is associated with cancers, such as breast cancer, lung cancer, liver cancer, colorectal cancer, and nasopharyngeal carcinoma. In these studies, a higher betaine intake resulted in a lower risk of cancer. Furthermore, research has suggested that cancer incidence could be decreased by 11% by consuming choline plus betaine (100 mg/day). However, in some studies, contradictory results have been found. For example, Lee and colleagues found no association between colorectal cancer and betaine intake. So far, most of these have been case–control studies; to obtain reliable results, placebo-controlled intervention trials and prospective studies will be needed. Recently, a study has shown that betaine intervention could restore hyperhomocysteine, which is a hallmark of Alzheimer’s disease, and attenuate the inflammatory reaction in Alzheimer’s disease patients. This finding further extended the range of betaine applications in human diseases.

In summary, despite some contradictory results, we propose that betaine may have an application in treatment or ameliorating symptoms of various huaman inflammatory diseases because of betaine’s significant anti-inflammatory effects. Notably, human diseases are undoubtedly more complex than animal disease models; therefore, to take advantage of the beneficial effects of betaine, researchers should continue to explore its mechanism and effects in humans.

Conclusion

In conclusion, this review discusses the major physiological role of betaine as an osmoprotectant and a methyl group donor, as well as the anti-inflammatory effects of betaine in various diseases. These effects are primarily associated with protecting SAA metabolism from oxidative stress, inhibiting NF-κB and NLRP3 inflammasome activity, regulating energy metabolism, and mitigating ER stress and apoptosis (Figure 2). Although the data from animal experiments are compelling, the clinical situation appears to be much more complex than originally thought. For example, despite various animal studies reporting the effects of betaine supplementation and some mechanisms, human studies have shown contradictory results. Future studies should focus on both animal and clinical experiments to reduce errors from separate experiment types and to ensure the medicinal value of betaine. More importantly, it is worthwhile to further investigate betaine because its significant anti-inflammatory effects could be beneficial for treating inflammatory diseases.

Author Contributions

YP, WR, and GZ designed the review article, and GZ wrote the review article. YP and WR revised the review article. CW, FH, NL, JD, GZ, and PL helped with designing figures and finding relevant literature. YP and WR approved the final manuscript.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest.

References 168

  1. 1.

    Yu D Xu Z Effects of betaine on growth performance and carcass characteristics in growing pigs. Asian-australas J Anim Sci (2004 ) 17(12):490–3.

    Not in our library10.5713/ajas.2004.1700

  2. 2.

    Craig SA. Betaine in human nutrition. Am J Clin Nutr (2004 ) 80(3):539.

    Not in our library10.1093/ajcn/80.3.539

  3. 3.

    Zeisel SH Mar MH Howe JC Holden JM. Concentrations of choline-containing compounds and betaine in common foods. J Nutr (2003 ) 133(5):1302–7.

    Not in our library10.1093/jn/133.5.1302

  4. 4.

    Zeisel SH. Metabolic crosstalk between choline/1-carbon metabolism and energy homeostasis. Clin Chem Lab Med (2013 ) 51(3):467–75.

    Not in our library10.1515/cclm-2012-0518

  5. 5.

    Davies SE Chalmers RA Randall EW Iles RA. Betaine metabolism in human neonates and developing rats. Clin Chim Acta (1988 ) 178(3):241–9.

    Not in our library10.1016/0009-8981(88)90232-x

  6. 6.

    Hoffmann L Brauers G Gehrmann T Haussinger D Mayatepek E Schliess F Osmotic regulation of hepatic betaine metabolism. Am J Physiol Gastrointest Liver Physiol (2013 ) 304(9):G835–46.

    Not in our library10.1152/ajpgi.00332.2012

  7. 7.

    Kempson SA Vovor-Dassu K Day C. Betaine transport in kidney and liver: use of betaine in liver injury. Cell Physiol Biochem (2013 ) 32(7):32–40.

    Not in our library10.1159/000356622

  8. 8.

    Geng CA Ma YB Zhang XM Yao SY Xue DQ Zhang RP Mulberrofuran G and isomulberrofuran G from Morus alba L.: anti-hepatitis B virus activity and mass spectrometric fragmentation. J Agric Food Chem (2012 ) 60(33):8197.

    Not in our library10.1021/jf302639b

  9. 9.

    Zhang M Wu X Lai F Zhang X Wu H Min T. Betaine inhibits hepatitis B virus with an advantage of decreasing resistance to lamivudine and interferon α. J Agric Food Chem (2016 ) 64(20):4068.

    Not in our library10.1021/acs.jafc.6b01180

  10. 10.

    Kathirvel E Morgan K Nandgiri G Sandoval BC Caudill MA Bottiglieri T Betaine improves nonalcoholic fatty liver and associated hepatic insulin resistance: a potential mechanism for hepatoprotection by betaine. Am J Physiol Gastrointest Liver Physiol (2010 ) 299(5):G1068.

    Not in our library10.1152/ajpgi.00249.2010

  11. 11.

    Jung YS Sun JK Kwon DY Ahn CW Kim YS Choi DW Alleviation of alcoholic liver injury by betaine involves an enhancement of antioxidant defense via regulation of sulfur amino acid metabolism. Food Chem Toxicol (2013 ) 62(12):292–8.

    Not in our library10.1016/j.fct.2013.08.049

  12. 12.

    Kim DH Kim SM Lee B Lee EK Chung KW Moon KM Effect of betaine on hepatic insulin resistance through FOXO1-induced NLRP3 inflammasome. J Nutr Biochem (2017 ) 45:104.

    Not in our library10.1016/j.jnutbio.2017.04.014

  13. 13.

    Kettunen H Peuranen S Tiihonen K Saarinen M. Intestinal uptake of betaine in vitro and the distribution of methyl groups from betaine, choline, and methionine in the body of broiler chicks. Comp Biochem Physiol A Mol Integr Physiol (2001 ) 128(2):269.

    Not in our library10.1016/s1095-6433(00)00301-9

  14. 14.

    Kettunen H Tiihonen K Peuranen S Saarinen MT Remus JC. Dietary betaine accumulates in the liver and intestinal tissue and stabilizes the intestinal epithelial structure in healthy and coccidia-infected broiler chicks. Comp Biochem Physiol A Mol Integr Physiol (2001 ) 130(4):759–69.

    Not in our library10.1016/s1095-6433(01)00410-x

  15. 15.

    Lever M Sizeland PC Frampton CM Chambers ST. Short and long-term variation of plasma glycine betaine concentrations in humans. Clin Biochem (2004 ) 37(3):184–90.

    Not in our library10.1016/j.clinbiochem.2003.11.004

  16. 16.
  17. 17.

    Knight LS Piibe Q Lambie I Perkins C Yancey PH. Betaine in the brain: characterization of betaine uptake, its influence on other osmolytes and its potential role in neuroprotection from osmotic stress. Neurochem Res (2017 ) 42(12):3490–503.

    Not in our library10.1007/s11064-017-2397-3

  18. 18.

    Day CR Kempson SA. Betaine chemistry, roles, and potential use in liver disease. Biochim Biophys Acta (2016 ) 1860(6):1098.

    Not in our library10.1016/j.bbagen.2016.02.001

  19. 19.

    Yancey PH. Organic osmolytes as compatible, metabolic and counteracting cytoprotectants in high osmolarity and other stresses. J Exp Biol (2005 ) 208(15):2819–30.

    Not in our library10.1242/jeb.01730

  20. 20.

    Neuhofer W Beck FX. Cell survival in the hostile environment of the renal medulla. Annu Rev Physiol (2005 ) 67(67):531–55.

    Not in our library10.1146/annurev.physiol.67.031103.154456

  21. 21.
  22. 22.

    Dasgupta M Kishore N. Selective inhibition of aggregation/fibrillation of bovine serum albumin by osmolytes: Mechanistic and energetics insights. Plos One (2017 ) 12(2):e0172208.

    Not in our library10.1371/journal.pone.0172208

  23. 23.

    Mcneil SD Nuccio ML Hanson AD Betaines and related osmoprotectants. Targets for metabolic engineering of stress resistance. Plant Physiol (1999 ) 120(4):945–9.

    Not in our library10.1104/pp.120.4.945

  24. 24.

    Veis JH Molitoris BA Teitelbaum I Mansour JA Berl T. Myo-inositol uptake by rat cultured inner medullary collecting tubule cells: effect of osmolality. Am J Physiol (1991 ) 260(5 Pt 2):F619.

    Not in our library10.1152/ajprenal.1991.260.5.f619

  25. 25.

    Bucolo C Fidilio A Cbm P Geraci F Lazzara F Drago F Antioxidant and osmoprotecting activity of taurine in dry eye models. Journal of Ocular Pharmacology & Therapeutics the Official Journal of the Association for Ocular Pharmacology & Therapeutics (2017 ) 34(1-2).

    Not in our library10.1089/jop.2017.0008

  26. 26.

    Adamczak B Wieczór M Kogut M Stangret J Czub J Molecular basis of the osmolyte effect on protein stability: lesson from the mechanical unfolding of lysozyme. Biochem J (2016 ) 473(20):3705–24.

    Not in our library10.1042/bcj20160604

  27. 27.

    Ratriyanto A Mosenthin R Bauer E Eklund M Metabolic, osmoregulatory and nutritional functions of betaine in monogastric animals. Asian-australas J Anim Sci (2009 ) 22(10):1461–76.

    Not in our library10.5713/ajas.2009.80659

  28. 28.

    Horio M Ito A Matsuoka Y Moriyama T Orita Y Takenaka M Apoptosis induced by hypertonicity in Madin Darley canine kidney cells: protective effect of betaine. Nephrol Dial Transplant (2001 ) 16(3):483–90.

    Not in our library10.1093/ndt/16.3.483

  29. 29.
  30. 30.

    Williams KT Schalinske KL. New insights into the regulation of methyl group and homocysteine metabolism. J Nutr (2007 ) 137(2):311–4.

    Not in our library10.1093/jn/137.2.311

  31. 31.

    Ueland PM Refsum H Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease, and drug therapy. J Lab Clin Med (1989 ) 114(5):473–501.

    Not in our library

  32. 32.

    Barak AJ Beckenhauer HC Tuma DJ. Betaine, ethanol, and the liver: a review. Alcohol (1996 ) 13(4):395–8.

    Not in our library10.1016/0741-8329(96)00030-4

  33. 33.

    Yamamoto A Takagi H Kitamura D Tatsuoka H Nakano H Kawano H Deficiency in protein l-isoaspartyl methyltransferase results in a fatal progressive epilepsy. J Neurosci (1998 ) 18(6):2063–74.

    Not in our library10.1523/jneurosci.18-06-02063.1998

  34. 34.

    Nishimakimogami T Yao Z Fujimori K. Inhibition of phosphatidylcholine synthesis via the phosphatidylethanolamine methylation pathway impairs incorporation of bulk lipids into VLDL in cultured rat hepatocytes. J Lipid Res (2002 ) 43(7):1035–45.

    Not in our library10.1194/jlr.m100354-jlr200

  35. 35.

    Boisvert FM Côté J Boulanger MC Richard S. A proteomic analysis of arginine-methylated protein complexes. Mol Cell Proteomics (2003 ) 2(12):1319.

    Not in our library10.1074/mcp.m300088-mcp200

  36. 36.

    Rando RR Chemical biology of isoprenylation/methylation. Biochem Soc Trans (1996 ) 24(3):682

    Not in our library10.1042/bst0240682

  37. 37.

    Kramer K Harrington EO Lu Q Bellas R Newton J Sheahan KL Isoprenylcysteine carboxyl methyltransferase activity modulates endothelial cell apoptosis. Mol Biol Cell (2003 ) 14(3):848.

    Not in our library10.1091/mbc.e02-07-0390

  38. 38.

    Kim DI Park MJ Lim SK Park JI Yoon KC Han HJ PRMT3 regulates hepatic lipogenesis through direct interaction with LXRα. Diabetes (2015 ) 64(1):60.

    Not in our library10.2337/db13-1394

  39. 39.

    Mosharov E Cranford MR Banerjee R. The quantitatively important relationship between homocysteine metabolism and glutathione synthesis by the transsulfuration pathway and its regulation by redox changes. Biochemistry (2000 ) 39(42):13005–11.

    Not in our library10.1021/bi001088w

  40. 40.

    Jung YS Kwak HE Choi KH Kim YC. Effect of acute ethanol administration on S-amino acid metabolism: increased utilization of cysteine for synthesis of taurine rather than glutathione. Adv Exp Med Biol (2003 ) 526:245.

    Not in our library10.1007/978-1-4615-0077-3_31

  41. 41.

    Meng B Gao W Wei J Yang J Wu J Pu L Quercetin reduces serum homocysteine level in rats fed a methionine-enriched diet. Nutrition (2013 ) 29(4):661–6.

    Not in our library10.1016/j.nut.2012.10.012

  42. 42.

    Cholewa JM Guimarães-Ferreira L Zanchi NE. Effects of betaine on performance and body composition: a review of recent findings and potential mechanisms. Amino Acids (2014 ) 46(8):1785.

    Not in our library10.1007/s00726-014-1748-5

  43. 43.

    Lawsonyuen A Levy HL. The use of betaine in the treatment of elevated homocysteine. Mol Genet Metab (2006 ) 88(3):201–7.

    Not in our library10.1016/j.ymgme.2006.02.004

  44. 44.

    Jin Z Mendu SK Birnir B. GABA is an effective immunomodulatory molecule. Amino Acids (2013 ) 45(1):87–94.

    Not in our library10.1007/s00726-011-1193-7

  45. 45.

    Sies H. Oxidative stress: oxidants and antioxidants. Exp Physiol (1997 ) 82(2):291–5.

    Not in our library10.1113/expphysiol.1997.sp004024

  46. 46.

    Davies KJ. Oxidative stress: the paradox of aerobic life. Biochem Soc Symp (1995 ) 61:1–31.

    Not in our library10.1042/bss0610001

  47. 47.

    Tsai MC Huang TL Increased activities of both superoxide dismutase and catalase were indicators of acute depressive episodes in patients with major depressive disorder. Psychiatry Research (2015 ) 235:38–42.

    Not in our library10.1016/j.psychres.2015.12.005

  48. 48.

    Tan DX Manchester LC Terron MP Flores LJ Reiter RJ. One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species? J Pineal Res (2007 ) 42(1):28–42.

    Not in our library10.1111/j.1600-079x.2006.00407.x

  49. 49.

    Dumaswala UJ Zhuo L Mahajan S Nair PN Shertzer HG Dibello P Glutathione protects chemokine-scavenging and antioxidative defense functions in human RBCs. Am J Physiol Cell Physiol (2001 ) 280(4):C867.

    Not in our library10.1152/ajpcell.2001.280.4.c867

  50. 50.

    Freitas I Boncompagni E Tarantola E Gruppi C Bertone V Ferrigno A In situ evaluation of oxidative stress in rat fatty liver induced by a methionine- and choline-deficient diet. Oxid Med Cell Longev (2016 ) 2016(3):9307064.

    Not in our library10.1155/2016/9307064

  51. 51.

    Zhang B Dong JL Chen YL Liu Y Huang SS Zhong XL Nrf2 mediates the protective effects of homocysteine by increasing the levels of GSH content in HepG2 cells. Mol Med Rep (2017 ) 16(1):597.

    Not in our library10.3892/mmr.2017.6633

  52. 52.

    Almashhadany A Shackebaei D Van der Touw T Jones GL Suleiman MS King N. Homocysteine exposure impairs myocardial resistance to ischaemia reperfusion and oxidative stress. Cell Physiol Biochem (2015 ) 37(6):2265–74.

    Not in our library10.1159/000438582

  53. 53.

    Baggott JE Tamura T. Homocysteine, iron and cardiovascular disease: a hypothesis. Nutrients (2015 ) 7(2):1108–18.

    Not in our library10.3390/nu7021108

  54. 54.

    Barak AJ Beckenhauer HC Badakhsh S Tuma DJ. The effect of betaine in reversing alcoholic steatosis. Alcohol Clin Exp Res (1997 ) 21(6):1100–2.

    Not in our library10.1111/j.1530-0277.1997.tb04259.x

  55. 55.

    Ji C Kaplowitz N. Betaine decreases hyperhomocysteinemia, endoplasmic reticulum stress, and liver injury in alcohol-fed mice. Gastroenterology (2003 ) 124(5):1488.

    Not in our library10.1016/s0016-5085(03)00276-2

  56. 56.

    Shinohara M Ji CN. Differences in betaine-homocysteine methyltransferase expression, endoplasmic reticulum stress response, and liver injury between alcohol-fed mice and rats. Hepatology (2010 ) 51(3):796.

    Not in our library10.1002/hep.23391

  57. 57.

    RC P Swarup D Dwivedi SK. Antioxidant effects of alpha tocopherol, ascorbic acid and l-methionine on lead induced oxidative stress to the liver, kidney and brain in rats. Toxicology (2001 ) 162(2):81.

    Not in our library10.1016/s0300-483x(01)00345-6

  58. 58.

    Martínez Y Li X Liu G Bin P Yan W Más D The role of methionine on metabolism, oxidative stress, and diseases. Amino Acids (2017 ) 49(12):2091–8.

    Not in our library10.1007/s00726-017-2494-2

  59. 59.

    Pastor A Collado PS Almar M Gonzálezgallego J. Microsomal function in biliary obstructed rats: effects of S-adenosylmethionine. J Hepatol (1996 ) 24(3):353–9.

    Not in our library10.1016/s0168-8278(96)80016-x

  60. 60.

    Cavallaro RA Fuso A Nicolia V Scarpa S. S-adenosylmethionine prevents oxidative stress and modulates glutathione metabolism in TgCRND8 mice fed a B-vitamin deficient diet. J Alzheimers Dis (2010 ) 20(4):997.

    Not in our library10.3233/jad-2010-091666

  61. 61.

    Barak AJ Beckenhauer HC Mailliard ME Kharbanda KK Tuma DJ. Betaine lowers elevated s-adenosylhomocysteine levels in hepatocytes from ethanol-fed rats. J Nutr (2003 ) 133(9):2845–8.

    Not in our library10.1093/jn/133.9.2845

  62. 62.

    Tehlivets O. Homocysteine as a risk factor for atherosclerosis: is its conversion to s-adenosyl-L-homocysteine the key to deregulated lipid metabolism? J Lipids (2011 ) 2011(2011):702853.

    Not in our library10.1155/2011/702853

  63. 63.

    Kwon DY Jung YS Kim SJ Park HK Park JH Kim YC. Impaired sulfur-amino acid metabolism and oxidative stress in nonalcoholic fatty liver are alleviated by betaine supplementation in rats. J Nutr (2009 ) 139(1):63.

    Not in our library10.3945/jn.108.094771

  64. 64.

    Kharbanda KK Todero SL King AL Osna NA Mcvicker BL Tuma DJ Betaine treatment attenuates chronic ethanol-induced hepatic steatosis and alterations to the mitochondrial respiratory chain proteome. Int J Hepatol (2011 ) 2012(16):962183

    Not in our library10.1155/2012/962183

  65. 65.

    Fernández-Checa JC Colell A García-Ruiz C. S-adenosyl-L-methionine and mitochondrial reduced glutathione depletion in alcoholic liver disease. Alcohol (2002 ) 27(3):179–83.

    Not in our library10.1016/s0741-8329(02)00229-x

  66. 66.

    Kim SJ Jung YS Kwon DY Kim YC. Alleviation of acute ethanol-induced liver injury and impaired metabolomics of S-containing substances by betaine supplementation. Biochem Biophys Res Commun (2008 ) 368(4):893.

    Not in our library10.1016/j.bbrc.2008.02.003

  67. 67.

    Bingül İ Aydın AF Başaran-Küçükgergin C Doğan-Ekici I Çoban J Doğru-Abbasoğlu S High-fat diet plus carbon tetrachloride-induced liver fibrosis is alleviated by betaine treatment in rats. Int Immunopharmacol (2016 ) 39:199.

    Not in our library10.1016/j.intimp.2016.07.028

  68. 68.

    Bingül İ Başaranküçükgergin C Aydın AF Çoban J Doğanekici I Doğruabbasoğlu S Betaine treatment decreased oxidative stress, inflammation, and stellate cell activation in rats with alcoholic liver fibrosis. Environ Toxicol Pharmacol (2016 ) 45:170.

    Not in our library10.1016/j.etap.2016.05.033

  69. 69.
  70. 70.

    Ron D Hyperhomocysteinemia and function of the endoplasmic reticulum. J Clin Invest (2001 ) 107(10):1221–2.

    Not in our library10.1172/jci13092

  71. 71.

    Pompella A Corti A Editorial: the changing faces of glutathione, a cellular protagonist. Biochem Pharmacol (2003 ) 66(8):1499

    Not in our library10.1016/s0006-2952(03)00504-5

  72. 72.

    Monaco C Andreakos E Kiriakidis S Mauri C Bicknell C Foxwell B Canonical pathway of nuclear factor kappa B activation selectively regulates proinflammatory and prothrombotic responses in human atherosclerosis. Proc Natl Acad Sci U S A (2004 ) 101(15):5634–9.

    Not in our library10.1073/pnas.0401060101

  73. 73.

    Aravilli RK Vikram SL Kohila V. Phytochemicals as potential antidotes for targeting NF-κB in rheumatoid arthritis. 3 Biotech (2017 ) 7(4):253.

    Not in our library10.1007/s13205-017-0888-1

  74. 74.
  75. 75.

    Go EK Jung KJ Kim JY Yu BP Chung HY. Betaine suppresses proinflammatory signaling during aging: the involvement of nuclear factor-kappaB via nuclear factor-inducing kinase/IkappaB kinase and mitogen-activated protein kinases. J Gerontol (2005 ) 60(10):1252.

    Not in our library10.1093/gerona/60.10.1252

  76. 76.

    Lee EK Jang EJ Jung KJ Kim DH Yu BP Chung HY Betaine attenuates lysophosphatidylcholine-mediated adhesion molecules in aged rat aorta: modulation of the nuclear factor-κB pathway. Exp Gerontol (2013 ) 48(5):517

    Not in our library10.1016/j.exger.2013.02.024

  77. 77.

    Yi EY Kim YJ Betaine inhibits in vitro and in vivo angiogenesis through suppression of the NF-kappaB and Akt signaling pathways. Int J Oncol (2012 ) 41(5):1879–85.

    Not in our library10.3892/ijo.2012.1616

  78. 78.

    Je JH Lee JY Jung KJ Sung B Go EK Yu BP NF-kappaB activation mechanism of 4-hydroxyhexenal via NIK/IKK and p38 MAPK pathway. FEBS Lett (2004 ) 566(1–3):183–9.

    Not in our library10.1016/j.febslet.2004.04.037

  79. 79.

    Kyriakis JM Avruch J. Mammalian MAPK signal transduction pathways activated by stress and inflammation: a 10-year update. Physiol Rev (2012 ) 92(2):689.

    Not in our library10.1152/physrev.00028.2011

  80. 80.

    Go EK Jung KJ Kim JM Lim H Lim HK Yu BP Betaine modulates age-related NF-κB by thiol-enhancing action. Biol Pharm Bull (2007 ) 30(12):2244–9.

    Not in our library10.1248/bpb.30.2244

  81. 81.

    Kim DH Sung B Kang YJ Jang JY Hwang SY Lee Y Anti-inflammatory effects of betaine on AOM/DSS-induced colon tumorigenesis in ICR male mice. Int J Oncol (2014 ) 45(3):1250.

    Not in our library10.3892/ijo.2014.2515

  82. 82.

    Li JM Ge CX Xu MX Wang W Yu R Fan CY Betaine recovers hypothalamic neural injury by inhibiting astrogliosis and inflammation in fructose-fed rats. Mol Nutr Food Res (2015 ) 59(2):189–202.

    Not in our library10.1002/mnfr.201400307

  83. 83.

    Zhang W Wang LW Wang LK Li X Zhang H Luo LP Betaine protects against high-fat-diet-induced liver injury by inhibition of high-mobility group box 1 and Toll-like receptor 4 expression in rats. Dig Dis Sci (2013 ) 58(11):3198.

    Not in our library10.1007/s10620-013-2775-x

  84. 84.

    Sims JE Smith DE. The IL-1 family: regulators of immunity. Nat Rev Immunol (2010 ) 10(2):89.

    Not in our library10.1038/nri2691

  85. 85.

    Martinon F Mayor A Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol (2009 ) 27(27):229.

    Not in our library10.1146/annurev.immunol.021908.132715

  86. 86.

    Lordnejad MR Schliess F Wettstein M Haussinger D. Modulation of the heme oxygenase HO-1 expression by hyperosmolarity and betaine in primary rat hepatocytes. Arch Biochem Biophys (2001 ) 388(2):285–92.

    Not in our library10.1006/abbi.2001.2297

  87. 87.

    Graf D Kurz AK Reinehr R Fischer R Kircheis G Häussinger D. Prevention of bile acid-induced apoptosis by betaine in rat liver. Hepatology (2002 ) 36(4):829–39.

    Not in our library10.1053/jhep.2002.35536

  88. 88.

    Kim SJ Lee SM. NLRP3 inflammasome activation in d-galactosamine and lipopolysaccharide-induced acute liver failure: role of heme oxygenase-1. Free Radic Biol Med (2013 ) 65(4):997.

    Not in our library10.1016/j.freeradbiomed.2013.08.178

  89. 89.

    Ge CX Yu R Xu MX Li PQ Fan CY Li JM Betaine prevented fructose-induced NAFLD by regulating LXRα/PPARα pathway and alleviating ER stress in rats. Eur J Pharmacol (2016 ) 770:154–64.

    Not in our library10.1016/j.ejphar.2015.11.043

  90. 90.

    Fan CY Wang MX Ge CX Wang X Li JM Kong LD. Betaine supplementation protects against high-fructose-induced renal injury in rats. J Nutr Biochem (2014 ) 25(3):353.

    Not in our library10.1016/j.jnutbio.2013.11.010

  91. 91.

    Van Der Heide LP Hoekman MF Smidt MP. The ins and outs of FoxO shuttling: mechanisms of FoxO translocation and transcriptional regulation. Biochem J (2004 ) 380(2):297–309.

    Not in our library10.1042/bj20040167

  92. 92.

    Accili D Arden KC. FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell (2004 ) 117(4):421–6.

    Not in our library10.1016/s0092-8674(04)00452-0

  93. 93.

    Li X Rong Y Zhang M Wang XL Lemaire SA Coselli JS Up-regulation of thioredoxin interacting protein (Txnip) by p38 MAPK and FOXO1 contributes to the impaired thioredoxin activity and increased ROS in glucose-treated endothelial cells. Biochem Biophys Res Commun (2009 ) 381(4):660–5.

    Not in our library10.1016/j.bbrc.2009.02.132

  94. 94.
  95. 95.
  96. 96.

    Li S Wang H Wang X Wang Y Feng J. Betaine affects muscle lipid metabolism via regulating the fatty acid uptake and oxidation in finishing pig. J Anim Sci Biotechnol (2017 ) 8(1):72.

    Not in our library10.1186/s40104-017-0200-6

  97. 97.

    Xu L Huang D Hu Q Wu J Wang Y Feng J. Betaine alleviates hepatic lipid accumulation via enhancing hepatic lipid export and fatty acid oxidation in rats fed with a high-fat diet. Br J Nutr (2015 ) 113(12):1835–43.

    Not in our library10.1017/s0007114515001130

  98. 98.

    Song Z Deaciuc I Zhou Z Song M Chen T Hill D Involvement of AMP-activated protein kinase in beneficial effects of betaine on high-sucrose diet-induced hepatic steatosis. Am J Physiol Gastrointest Liver Physiol (2007 ) 293(4):G894.

    Not in our library10.1152/ajpgi.00133.2007

  99. 99.

    Du J Shen L Tan Z Zhang P Zhao X Xu Y Betaine supplementation enhances lipid metabolism and improves insulin resistance in mice fed a high-fat diet. Nutrients (2018 ) 10(2).

    Not in our library10.3390/nu10020131

  100. 100.
  101. 101.

    Li Y Xu S Mihaylova M Zheng B Hou X Jiang B AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin resistant mice. Cell Metab (2011 ) 13(4):376–88.

    Not in our library10.1016/j.cmet.2011.03.009

  102. 102.

    Russell RR III Bergeron R Shulman GI Young LH. Translocation of myocardial GLUT-4 and increased glucose uptake through activation of AMPK by AICAR. Am J Physiol (1999 ) 277(2):643–9.

    Not in our library10.1152/ajpheart.1999.277.2.h643

  103. 103.

    Sang-Min J. Regulation and function of AMPK in physiology and diseases. Exp Mol Med (2016 ) 48(7):e245.

    Not in our library10.1038/emm.2016.81

  104. 104.

    Huypens P Moens K Heimberg H Ling Z Pipeleers D Van de Casteele M. Adiponectin-mediated stimulation of AMP-activated protein kinase (AMPK) in pancreatic beta cells. Life Sci (2005 ) 77(11):1273–82.

    Not in our library10.1016/j.lfs.2005.03.008

  105. 105.

    Bonnard C Durand A Vidal H Rieusset J. Changes in adiponectin, its receptors and AMPK activity in tissues of diet-induced diabetic mice. Diabetes Metab (2008 ) 34(1):52–61.

    Not in our library10.1016/j.diabet.2007.09.006

  106. 106.

    Olli K Lahtinen S Rautonen N Tiihonen K. Betaine reduces the expression of inflammatory adipokines caused by hypoxia in human adipocytes. Br J Nutr (2013 ) 109(1):43–9.

    Not in our library10.1017/s0007114512000888

  107. 107.

    Wang Z Yao T Pini M Zhou Z Fantuzzi G Song Z. Betaine improved adipose tissue function in mice fed a high-fat diet: a mechanism for hepatoprotective effect of betaine in nonalcoholic fatty liver disease. Am J Physiol Gastrointest Liver Physiol (2010 ) 298(5):G634.

    Not in our library10.1152/ajpgi.00249.2009

  108. 108.

    Wang L Chen L Tan Y Wei J Chang Y Jin T Betaine supplement alleviates hepatic triglyceride accumulation of apolipoprotein E deficient mice via reducing methylation of peroxisomal proliferator-activated receptor alpha promoter. Lipids Health Dis (2013 ) 12(1):34.

    Not in our library10.1186/1476-511x-12-34

  109. 109.

    Kim DH Lee B Min HP Min JK An HJ Lee EK Molecular mechanism of betaine on hepatic lipid metabolism: inhibition of FoxO1 binding to PPARg. J Agric Food Chem (2016 ) 64(36):6819

    Not in our library10.1021/acs.jafc.6b02644

  110. 110.

    Hagar H Medany AE Salam R Medany GE Nayal OA. Betaine supplementation mitigates cisplatin-induced nephrotoxicity by abrogation of oxidative/nitrosative stress and suppression of inflammation and apoptosis in rats. Exp Toxicol Pathol (2015 ) 67(2):133–41.

    Not in our library10.1016/j.etp.2014.11.001

  111. 111.

    Kharbanda KK Todero SL Ward BW Tuma DJ. Betaine administration corrects ethanol-induced defective VLDL secretion. Mol Cell Biochem (2009 ) 327(1–2):75–8.

    Not in our library10.1007/s11010-009-0044-2

  112. 112.

    Huang LS Voyiaziakis E Markenson DF Sokol KA Hayek T Breslow JL. apo B gene knockout in mice results in embryonic lethality in homozygotes and neural tube defects, male infertility, and reduced HDL cholesterol ester and apo A-I transport rates in heterozygotes. J Clin Invest (1995 ) 96(5):2152–61.

    Not in our library10.1172/jci118269

  113. 113.

    Wellen KE Hotamisligil GS Inflammation, stress, and diabetes. J Clin Invest (2005 ) 115(5):1111–9.

    Not in our library10.1172/jci200525102

  114. 114.

    Barazzoni R Gortan Cappellari G Ragni M Nisoli E. Insulin resistance in obesity: an overview of fundamental alterations. Eat Weight Disord (2018 ) 23(2):149–57.

    Not in our library10.1007/s40519-018-0481-6

  115. 115.

    Schultze SM Hemmings BA Markus N Oliver T. PI3K/AKT, MAPK and AMPK signalling: protein kinases in glucose homeostasis. Exp Rev Mol Med (2012 ) 14:e1.

    Not in our library10.1017/s1462399411002109

  116. 116.

    Song G Ouyang G Bao S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med (2005 ) 9(1):59–71.

    Not in our library10.1111/j.1582-4934.2005.tb00337.x

  117. 117.

    Burgess SC He TT Yan Z Lindner J Sherry AD Malloy CR Cytosolic phosphoenolpyruvate carboxykinase does not solely control the rate of hepatic gluconeogenesis in the intact mouse liver. Cell Metab (2007 ) 5(4):313

    Not in our library10.1016/j.cmet.2007.03.004

  118. 118.

    Plyte SE Hughes K Nikolakaki E Pulverer BJ Woodgett JR. Glycogen synthase kinase-3: functions in oncogenesis and development. Biochim Biophys Acta (1992 ) 1114(2–3):147–62.

    Not in our library10.1016/0304-419x(92)90012-n

  119. 119.

    Iwasaki H. Impaired PRMT1 activity in the liver and pancreas of type 2 diabetic Goto-Kakizaki rats. Life Sci (2009 ) 85(3–4):161.

    Not in our library10.1016/j.lfs.2009.05.007

  120. 120.

    Iwasaki H. Involvement of PRMT1 in hnRNPQ activation and internalization of insulin receptor. Biochem Biophys Res Commun (2008 ) 372(2):314–9.

    Not in our library10.1016/j.bbrc.2008.05.051

  121. 121.

    Iwasaki H Yada T. Protein arginine methylation regulates insulin signaling in L6 skeletal muscle cells. Biochem Biophys Res Commun (2007 ) 364(4):1015.

    Not in our library10.1016/j.bbrc.2007.10.113

  122. 122.

    Sparks JD Collins HL Chirieac DV Cianci J Jokinen J Sowden MP Hepatic VLDL and apolipoprotein B production are increased following in vivo induction of betaine-homocysteine S-methyltransferase. Biochem J (2006 ) 395(2):363–71.

    Not in our library10.1042/bj20051966

  123. 123.

    Cross DAE Alessi DR Cohen P Andjelkovich M Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature (1995 ) 378(6559):785–9.

    Not in our library10.1038/378785a0

  124. 124.

    Matsumoto M Pocai A Rossetti L Depinho RA Accili D. Impaired regulation of hepatic glucose production in mice lacking the forkhead transcription factor Foxo1 in liver. Cell Metab (2007 ) 6(3):208–16.

    Not in our library10.1016/j.cmet.2007.08.006

  125. 125.

    Zhou Y Lee J Reno CM Sun C Sang WP Chung J Regulation of glucose homeostasis through a XBP-1–FoxO1 interaction. Nat Med (2011 ) 17(3):356–65.

    Not in our library10.1038/nm.2293

  126. 126.

    Schröder M Kaufman RJ. ER stress and the unfolded protein response. Mutat Res (2005 ) 569(1):29–63.

    Not in our library10.1016/j.mrfmmm.2004.06.056

  127. 127.

    Zheng YZ Cao ZG Hu X Shao ZM. The endoplasmic reticulum stress markers GRP78 and CHOP predict disease-free survival and responsiveness to chemotherapy in breast cancer. Breast Cancer Res Treat (2014 ) 145(2):349–58.

    Not in our library10.1007/s10549-014-2967-x

  128. 128.

    Kondylis V Kumari S Vlantis K Pasparakis M. The interplay of IKK, NF-κB and RIPK1 signaling in the regulation of cell death, tissue homeostasis and inflammation. Immunol Rev (2017 ) 277(1):113.

    Not in our library10.1111/imr.12550

  129. 129.

    Larsen BD Rampalli S Burns LE Brunette S Dilworth FJ Megeney LA. Caspase 3/caspase-activated DNase promote cell differentiation by inducing DNA strand breaks. Proc Natl Acad Sci U S A (2010 ) 107(9):4230–5.

    Not in our library10.1073/pnas.0913089107

  130. 130.

    Ji C Shinohara M Kuhlenkamp J Chan C Kaplowitz N Mechanisms of protection by the betaine-homocysteine methyltransferase/betaine system in HepG2 cells and primary mouse hepatocytes. Hepatology (2010 ) 46(5):1586–96.

    Not in our library10.1002/hep.21854

  131. 131.

    Gaur N Karouzakis E Glück S Bagdonas E Jüngel A Michel BA MicroRNAs interfere with DNA methylation in rheumatoid arthritis synovial fibroblasts. RMD Open (2016 ) 2(2):e000299.

    Not in our library10.1136/rmdopen-2016-000299

  132. 132.

    Kharbanda KK Rogers DD II Mailliard ME Siford GL Barak AJ Beckenhauer HC Role of elevated S-adenosylhomocysteine in rat hepatocyte apoptosis: protection by betaine. Biochem Pharmacol (2005 ) 70(12):1883–90.

    Not in our library10.1016/j.bcp.2005.09.021

  133. 133.

    Garrett Q Khandekar N Shih S Flanagan JL Simmons P Vehige J Betaine stabilizes cell volume and protects against apoptosis in human corneal epithelial cells under hyperosmotic stress. Exp Eye Res (2013 ) 108(3):33–41.

    Not in our library10.1016/j.exer.2012.12.001

  134. 134.

    Konstantinova SV Tell GS Vollset SE Nygård O Bleie Ø Ueland PM. Divergent associations of plasma choline and betaine with components of metabolic syndrome in middle age and elderly men and women. J Nutr (2008 ) 138(5):914.

    Not in our library10.1093/jn/138.5.914

  135. 135.

    Chen YM Liu Y Liu YH Wang X Guan K Zhu HL Higher serum concentrations of betaine rather than choline is associated with better profiles of DXA-derived body fat and fat distribution in Chinese adults. Int J Obes (2014 ) 39(3):465

    Not in our library10.1038/ijo.2014.158

  136. 136.

    Schartumhansen H Ueland PM Pedersen ER Meyer K Ebbing M Bleie Ø Assessment of urinary betaine as a marker of diabetes mellitus in cardiovascular patients. PLoS One (2013 ) 8(8):e69454.

    Not in our library10.1371/journal.pone.0069454

  137. 137.

    Lever M Slow S Mcgregor DO Dellow WJ George PM Chambers ST. Variability of plasma and urine betaine in diabetes mellitus and its relationship to methionine load test responses: an observational study. Cardiovasc Diabetol (2012 ) 11(1):34.

    Not in our library10.1186/1475-2840-11-34

  138. 138.

    Dellow WJ Chambers ST Lever M Lunt H Robson RA. Elevated glycine betaine excretion in diabetes mellitus patients is associated with proximal tubular dysfunction and hyperglycemia. Diabetes Res Clin Pract (1999 ) 43(2):91–9.

    Not in our library10.1016/s0168-8227(98)00115-6

  139. 139.

    Ying J Rahbar MH Hallman DM Hernandez LM Spitz MR Forman MR Associations between dietary intake of choline and betaine and lung cancer risk. PLoS One (2013 ) 8(2):e54561.

    Not in our library10.1371/journal.pone.0054561

  140. 140.

    Zeng F Xu C Liu Y Fan Y Lin X Lu Y Choline and betaine intakes are associated with reduced risk of nasopharyngeal carcinoma in adults: a case–control study. Br J Cancer (2014 ) 110(3):808

    Not in our library10.1038/bjc.2013.686

  141. 141.

    Madsen SK Rajagopalan P Joshi SH Toga AW Thompson PM. Higher homocysteine associated with thinner cortical gray matter in 803 participants from the Alzheimer’s disease neuroimaging initiative. Neurobiol Aging (2015 ) 36:S203–10.

    Not in our library10.1016/j.neurobiolaging.2014.01.154

  142. 142.

    Huang QC Xu ZR Han XY Li WF Changes in hormones, growth factor and lipid metabolism in finishing pigs fed betaine—livestock science. Livest Sci (2006 ) 105(1):78–85.

    Not in our library10.1016/j.livsci.2006.04.031

  143. 143.

    He S Zhao S Dai S Liu D Bokhari SG. Effects of dietary betaine on growth performance, fat deposition and serum lipids in broilers subjected to chronic heat stress. Anim Sci J (2015 ) 86(10):897.

    Not in our library10.1111/asj.12372

  144. 144.

    Gao X Randell E Zhou H Sun G. Higher serum choline and betaine levels are associated with better body composition in male but not female population. PLoS One (2018 ) 13(2):e0193114.

    Not in our library10.1371/journal.pone.0193114

  145. 145.

    Schwab U Törrönen A Toppinen L Alfthan G Saarinen M Aro A Betaine supplementation decreases plasma homocysteine concentrations but does not affect body weight, body composition, or resting energy expenditure in human subjects. Am J Clin Nutr (2002 ) 76(5):961.

    Not in our library10.1093/ajcn/76.5.961

  146. 146.

    Favero SD Roschel H Artioli G Ugrinowitsch C Tricoli V Costa A Creatine but not betaine supplementation increases muscle phosphorylcreatine content and strength performance. Amino Acids (2012 ) 42(6):2299–305.

    Not in our library10.1007/s00726-011-0972-5

  147. 147.

    Gao X Wang Y Edward R Pardis P Yi Y Wayne G Higher dietary choline and betaine intakes are associated with better body composition in the adult population of Newfoundland, Canada. PLoS One (2016 ) 11(5):e0155403.

    Not in our library10.1371/journal.pone.0155403

  148. 148.

    Sookoian S Puri P Castaño GO Scian R Mirshahi F Sanyal AJ Nonalcoholic steatohepatitis is associated with a state of betaine-insufficiency. Liver Int (2016 ) 150(4):S1140–1.

    Not in our library10.1111/liv.13249

  149. 149.
  150. 150.

    Miglio F Rovati LC Santoro A Setnikar I. Efficacy and safety of oral betaine glucuronate in non-alcoholic steatohepatitis. A double-blind, randomized, parallel-group, placebo-controlled prospective clinical study. Arzneimittelforschung (2000 ) 50(8):722–7.

    Not in our library10.1055/s-0031-1300279

  151. 151.

    Abdelmalek MF Soangulo S. Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. Hepatology (2009 ) 50(6):1818–26.

    Not in our library10.1002/hep.23239

  152. 152.

    Tiihonen K Saarinen MT Alhoniemi E Mitsuya N Yamaki G Effect of dietary betaine on metabolic syndrome risk factors in Asian males with mild fatty liver. Journal of Diabetes and Metabolism (2016 ) 7:692

    Not in our library10.4172/2155-6156.1000692

  153. 153.

    Jung GY Won SB Kim J Jeon S Han A Kwon YH Betaine Alleviates Hypertriglycemia and Tau Hyperphosphorylation in db/db Mice. Toxicological Research (2013 ) 29(1):7

    Not in our library10.5487/tr.2013.29.1.007

  154. 154.

    Kim YG Lim HH Lee SH Shin MS Kim CJ Yang HJ. Betaine inhibits vascularization via suppression of Akt in the retinas of streptozotocin-induced hyperglycemic rats. Mol Med Rep (2015 ) 12(2):1639.

    Not in our library10.3892/mmr.2015.3613

  155. 155.

    Kitabchi AE Umpierrez GE Miles JM Fisher JN Hyperglycemic crises in adult patients with diabetes. Diabetes Care (2009 ) 32(12):e157; author reply e8

    Not in our library10.2337/dc09-9032

  156. 156.

    Lever M Sizeland PCB Bason LM Hayman CM Robson RA Chambers ST. Abnormal glycine betaine content of the blood and urine of diabetic and renal patients. Clin Chim Acta (1994 ) 230(1):69.

    Not in our library10.1016/0009-8981(94)90090-6

  157. 157.

    Dullaart RPF Erwin G Elias J Gruppen EG Connelly MA. Plasma phospholipid transfer protein activity is inversely associated with betaine in diabetic and non-diabetic subjects. Lipids Health Dis (2016 ) 15(1):143.

    Not in our library10.1186/s12944-016-0313-5

  158. 158.

    Chen L Chen YM Wang LJ Wei J Tan YZ Zhou JY Higher homocysteine and lower betaine increase the risk of microangiopathy in patients with diabetes mellitus carrying the GG genotype of PEMT G774C. Diabetes Metab Res Rev (2013 ) 29(8):607–17.

    Not in our library10.1002/dmrr.2432

  159. 159.

    Mcentyre CJ Lever M Chambers ST George PM Slow S Elmslie JL Variation of betaine, N,N-dimethylglycine, choline, glycerophosphorylcholine, taurine and trimethylamine-N-oxide in the plasma and urine of overweight people with type 2 diabetes over a two-year period. Ann Clin Biochem (2015 ) 52(Pt 3):352.

    Not in our library10.1177/0004563214545346

  160. 160.

    Rabinowitch IM Effects of betaine upon the cholesterol and bilirubin contents of blood plasma in diabetes mellitus. Can Med Assoc J (1936 ) 34(6):637.

    Not in our library

  161. 161.

    Xu X Gammon MD Zeisel SH Bradshaw PT Wetmur JG Teitelbaum SL High intakes of choline and betaine reduce breast cancer mortality in a population-based study. FASEB J (2009 ) 23(11):4022–8.

    Not in our library10.1096/fj.09-136507

  162. 162.

    Lu MS Fang YJ Pan ZZ Zhong X Zheng MC Chen YM Choline and betaine intake and colorectal cancer risk in Chinese population: a case–control study. PLoS One (2015 ) 10(3):e0118661.

    Not in our library10.1371/journal.pone.0118661

  163. 163.

    Zhou RF Chen XL Zhou ZG Zhang YJ Lan QY Liao GC Higher dietary intakes of choline and betaine are associated with a lower risk of primary liver cancer: a case-control study. Sci Rep (2017 ) 7(1):679.

    Not in our library10.1038/s41598-017-00773-w

  164. 164.

    Sun S Li X Ren A Du M Du H Shu Y Choline and betaine consumption lowers cancer risk: a meta-analysis of epidemiologic studies. Sci Rep (2016 ) 6:35547.

    Not in our library10.1038/srep35547

  165. 165.

    Lee JE Giovannucci E Fuchs CS Willett WC Zeisel SH Cho E. Choline and betaine intake and the risk of colorectal cancer in men. Cancer Epidemiol Biomarkers Prev (2010 ) 19(3):884–7.

    Not in our library10.1158/1055-9965.epi-09-1295

  166. 166.

    Cho E Holmes M Hankinson SE Willett WC. Nutrients involved in one-carbon metabolism and risk of breast cancer among premenopausal women. Cancer Epidemiol Biomarkers Prev (2007 ) 16(12):2787.

    Not in our library10.1158/1055-9965.epi-07-0683

  167. 167.

    Sun J Wen S Zhou J Ding S. Association between malnutrition and hyperhomocysteine in Alzheimer’s disease patients and diet intervention of betaine. J Clin Lab Anal (2017 ) 31(5):1–7.

    Not in our library10.1002/jcla.22090

  168. 168.

    Detopoulou P Panagiotakos DB Antonopoulou S Pitsavos C Stefanadis C. Dietary choline and betaine intakes in relation to concentrations of inflammatory markers in healthy adults: the ATTICA study. Am J Clin Nutr (2008 ) 87(2):424–30.

    Not in our library10.1093/ajcn/87.2.424

Cited by papers we hold 2

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.